Abstract:Key PointsAttempts to target RAS pharmaceutically have not yet yielded small molecules with sufficient potency and drug-like characteristics to be useful, but additional approaches are underway.Inhibitors of RAS membrane interaction and subcellular localization remain attractive targets for therapeutic intervention. In this regard, recent discoveries of functionally relevant post-translational modifications of RAS, such as phosphorylation and ubiquitylation, suggest new opportunities to block RAS function.Inhibitors of RAS effector signalling are currently centred on the RAF–MEK–ERK and PI3K–AKT–TOR pathways, with many inhibitors of components of these two pathways under clinical evaluation. The less well-studied effector pathways that lead to activation of RAL and RAC small GTPases are also promising targets.Despite some setbacks owing to issues of reproducibility, functional screens for synthetic lethal interactors with oncogenic RAS remain an attractive approach to identify novel drug targets for RAS-driven cancers.RAS-driven cancers become efficient scavengers of nutrients and may rely on pathways such as autophagy and macropinocytosis. Furthermore, oncogenic KRAS has a crucial role in altering tumour metabolism, including rewiring of both glucose- and glutamine-dependent metabolic pathways. These alterations could provide the opportunity for novel therapeutic interventions.Inhibitors of RAS membrane interaction and subcellular localization remain attractive targets for therapeutic intervention. In this regard, recent discoveries of functionally relevant post-translational modifications of RAS, such as phosphorylation and ubiquitylation, suggest new opportunities to block RAS function.RAS-driven cancers become efficient scavengers of nutrients and may rely on pathways such as autophagy and macropinocytosis. Furthermore, oncogenic KRAS has a crucial role in altering tumour metabolism, including rewiring of both glucose- and glutamine-dependent metabolic pathways. These alterations could provide the opportunity for novel therapeutic interventions.

Potential Drug Targets Based on the Ras Signal Transduction Pathways:a Review

Major Physiological Signaling Pathways in the Regulation of Cell Proliferation and Survival

Research Progress in the Mechanism of Molecular Targeted Anti-tumor Drugs

Drugging Ras Gtpase: A Comprehensive Mechanistic And Signaling Structural View

Drugging Ras GTPase: a Comprehensive Mechanistic and Signaling Structural View.

Targeting RAS Phosphorylation in Cancer Therapy: Mechanisms and Modulators

Signaling Passway and Related Biological Function Mediated by R-Ras

Targeting RAS mutants in malignancies: successes, failures, and reasons for hope

Cdc42 Signaling Pathway Inhibition as a Therapeutic Target in Ras- Related Cancers

Key signal transduction pathways and crosstalk in cancer: Biological and therapeutic opportunities

One Step Closer to Targeting RAS.

Development and safety of investigational and approved drugs targeting the RAS function regulation in RAS mutant cancers

RAS‐targeted cancer therapy: Advances in drugging specific mutations

Fragment-based Drug Discovery of Inhibitors to Block PDEdelta-RAS Protein-Protein Interaction

Targeting Rabs As a Novel Therapeutic Strategy for Cancer Therapy.

Targeting Signaling Pathway Networks in Several Malignant Tumors: Progresses and Challenges

Drugging the undruggable RAS: Mission Possible?

Cdc42 Signaling Pathway Inhibition As a Therapeutic Target in Ras- Related Cancers.

Post-translational modification of KRAS: potential targets for cancer therapy

Advances in the Development of Rho GTPase Inhibitors

Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy